MXPA03011453A - Acetilacion de fragmentos de gp41. - Google Patents
Acetilacion de fragmentos de gp41.Info
- Publication number
- MXPA03011453A MXPA03011453A MXPA03011453A MXPA03011453A MXPA03011453A MX PA03011453 A MXPA03011453 A MX PA03011453A MX PA03011453 A MXPA03011453 A MX PA03011453A MX PA03011453 A MXPA03011453 A MX PA03011453A MX PA03011453 A MXPA03011453 A MX PA03011453A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- antifusogenic
- fusion
- amino acids
- host cell
- Prior art date
Links
- 101800001690 Transmembrane protein gp41 Proteins 0.000 title 1
- 230000021736 acetylation Effects 0.000 title 1
- 238000006640 acetylation reaction Methods 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 12
- 230000004927 fusion Effects 0.000 abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 210000003000 inclusion body Anatomy 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a un proceso para la produccion de un peptido antifusogenico de una longitud de aproximadamente 10 hasta 50 aminoacidos en una celula hospedera procariotica, caracterizado porque, bajo tales condiciones en que los cuerpos de inclusion del peptido antifusogenico o el peptido de fusion son formados, a) en la celula hospedera existe expresado un acido nucleico que codifica el peptido antifusogenico como un peptido diferente del de fusion o que codifica un peptido de fusion de una longitud de aproximadamente 14 hasta 70 aminoacidos que consiste del peptido antifusogenico enlazado N-terminalmente a un peptido adicional de una longitud de aproximadamente 4 hasta 30 aminoacidos; b) la celula hospedera es cultivada; c) los cuerpos de inclusion son recuperados y solubilizados; d) en el caso del peptido de fusion el peptido antifusogenico es retirado por segmentacion del peptido adicional; y e) el peptido antifusogenico es aislado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01114497 | 2001-06-15 | ||
| PCT/EP2002/005782 WO2002103026A2 (en) | 2001-06-15 | 2002-05-27 | Method for the recombinant production of peptidic antiviral fusion inhibitors, and acetylation of gb41 fragments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03011453A true MXPA03011453A (es) | 2004-04-05 |
Family
ID=8177732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03011453A MXPA03011453A (es) | 2001-06-15 | 2002-05-27 | Acetilacion de fragmentos de gp41. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6858410B2 (es) |
| EP (1) | EP1402050B1 (es) |
| JP (1) | JP4267444B2 (es) |
| KR (2) | KR100614714B1 (es) |
| CN (1) | CN1255548C (es) |
| AU (1) | AU2002314111A1 (es) |
| CA (1) | CA2450548C (es) |
| ES (1) | ES2525317T3 (es) |
| MX (1) | MXPA03011453A (es) |
| WO (1) | WO2002103026A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1255548C (zh) | 2001-06-15 | 2006-05-10 | 霍夫曼-拉罗奇有限公司 | gp41片段的乙酰化 |
| CA2443365C (en) * | 2002-11-19 | 2010-01-12 | F. Hoffmann-La Roche Ag | Methods for the recombinant production of antifusogenic peptides |
| JP2007515965A (ja) * | 2003-12-23 | 2007-06-21 | セントカー・インコーポレーテツド | 抗レトロウイルス性の剤、組成物、方法および用途 |
| WO2007056083A2 (en) * | 2005-11-02 | 2007-05-18 | Ambrx, Inc. | Biosynthetic polypeptide fusion inhibitors |
| GB0608368D0 (en) * | 2006-04-28 | 2006-06-07 | Isis Innovation | Process for making Oligopeptides |
| TW200817438A (en) * | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
| US20090143288A1 (en) | 2007-03-13 | 2009-06-04 | Roche Palo Alto Llc | Peptide-complement conjugates |
| AU2012362121B2 (en) * | 2011-12-29 | 2017-08-03 | Dana-Farber Cancer Institute, Inc. | Stabilized antiviral fusion helices |
| WO2014012090A1 (en) | 2012-07-13 | 2014-01-16 | The Broad Institute, Inc. | Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof |
| CN109069578A (zh) | 2016-02-29 | 2018-12-21 | 达纳-法伯癌症研究所股份有限公司 | 用于治疗感染的钉合的细胞内靶向抗微生物肽 |
| US11325955B2 (en) | 2017-07-19 | 2022-05-10 | Dana-Farber Cancer Institute, Inc. | Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9667A (en) * | 1853-04-12 | Washiug-machine | ||
| US123039A (en) * | 1872-01-23 | Improvement in canal-boats | ||
| DE3034045A1 (de) | 1980-09-10 | 1982-04-22 | Boehringer Mannheim Gmbh, 6800 Mannheim | Endoproteinase-lys-c aus bakterien, verfahren zu ihrer gewinnung und verwendung |
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US4511503A (en) * | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US5453363A (en) | 1985-10-23 | 1995-09-26 | Boehringer Mannheim Gmbh | Process for the activation of t-PA or Ing after genetic expression in prokaryotes |
| CU22222A1 (es) * | 1989-08-03 | 1995-01-31 | Cigb | Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes |
| US5595887A (en) | 1990-07-16 | 1997-01-21 | Bionebraska, Inc. | Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment |
| DE69332377T2 (de) | 1992-07-13 | 2003-07-03 | Bionebraska, Inc. | Verfahren zur modifizierung rekombinanter polypeptide |
| US5656456A (en) | 1992-07-13 | 1997-08-12 | Bionebraska, Inc. | Chemical method for selective modification of the N- and/or C-terminal amino acid α-carbon reactive group of a recombinant polypeptide or a portion thereof |
| WO1994002505A1 (en) | 1992-07-20 | 1994-02-03 | Duke University | Compounds which inhibit hiv replication |
| DE69332740T2 (de) * | 1992-08-21 | 2004-02-05 | The University Of British Columbia, Vancouver | Kationische peptide und verfahren zu deren herstellung |
| US6017536A (en) | 1993-06-07 | 2000-01-25 | Trimeris, Inc. | Simian immunodeficiency virus peptides with antifusogenic and antiviral activities |
| US6479055B1 (en) | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| US5512459A (en) | 1993-07-20 | 1996-04-30 | Bionebraska, Inc. | Enzymatic method for modification or recombinant polypeptides |
| US5648244A (en) * | 1993-09-27 | 1997-07-15 | President And Fellows Of Harvard College | Production, purification, cleavage and use of fusion peptides |
| DE4405810A1 (de) * | 1994-02-23 | 1995-08-24 | Behringwerke Ag | Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung |
| CA2224008C (en) * | 1995-06-07 | 2009-08-18 | Trimeris, Inc. | The treatment of hiv and other viral infections using combinatorial therapy |
| US6846905B2 (en) * | 1997-08-15 | 2005-01-25 | Abbott Laboratories | Antigen constructs useful in the detection and differentiation of antibodies to HIV |
| CA2324348C (en) | 1998-03-23 | 2006-03-14 | Trimeris, Inc. | Methods and compositions for peptide synthesis |
| US6258782B1 (en) | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| US6656906B1 (en) | 1998-05-20 | 2003-12-02 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| CN1170932C (zh) * | 1998-07-10 | 2004-10-13 | 赛欧斯公司 | 生产等电点高于8或低于5的多肽的方法 |
| WO2000031279A2 (en) | 1998-11-20 | 2000-06-02 | Micrologix Biotech Inc. | Producing antimicrobial cationic peptides as fusion proteins |
| EP1149115A4 (en) * | 1999-01-08 | 2005-11-02 | Panacos Pharmaceuticals Inc | TECHNIQUES FOR ELICITATION OF NEUTRALIZING ANTIBODIES TARGETING HIV-1 gp41 |
| US7582301B1 (en) | 1999-05-17 | 2009-09-01 | Conjuchem Biotechnologies, Inc. | Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides |
| ES2296665T3 (es) * | 1999-12-16 | 2008-05-01 | Whitehead Institute For Biomedical Research | Proteina cinco-helice. |
| CN1255548C (zh) | 2001-06-15 | 2006-05-10 | 霍夫曼-拉罗奇有限公司 | gp41片段的乙酰化 |
-
2002
- 2002-05-27 CN CNB028119533A patent/CN1255548C/zh not_active Expired - Fee Related
- 2002-05-27 AU AU2002314111A patent/AU2002314111A1/en not_active Abandoned
- 2002-05-27 JP JP2003505348A patent/JP4267444B2/ja not_active Expired - Fee Related
- 2002-05-27 EP EP02740652.9A patent/EP1402050B1/en not_active Expired - Lifetime
- 2002-05-27 ES ES02740652.9T patent/ES2525317T3/es not_active Expired - Lifetime
- 2002-05-27 CA CA2450548A patent/CA2450548C/en not_active Expired - Fee Related
- 2002-05-27 WO PCT/EP2002/005782 patent/WO2002103026A2/en active Application Filing
- 2002-05-27 KR KR1020037016312A patent/KR100614714B1/ko not_active IP Right Cessation
- 2002-05-27 MX MXPA03011453A patent/MXPA03011453A/es active IP Right Grant
- 2002-05-30 US US10/158,742 patent/US6858410B2/en not_active Expired - Fee Related
-
2004
- 2004-10-20 US US10/969,624 patent/US7348423B2/en not_active Expired - Fee Related
-
2006
- 2006-03-31 KR KR10-2006-7006344A patent/KR100694919B1/ko not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040010705A (ko) | 2004-01-31 |
| WO2002103026A2 (en) | 2002-12-27 |
| KR100694919B1 (ko) | 2007-03-14 |
| US6858410B2 (en) | 2005-02-22 |
| WO2002103026A3 (en) | 2003-11-20 |
| US20050058659A1 (en) | 2005-03-17 |
| CN1255548C (zh) | 2006-05-10 |
| US20030104581A1 (en) | 2003-06-05 |
| JP4267444B2 (ja) | 2009-05-27 |
| AU2002314111A1 (en) | 2003-01-02 |
| KR100614714B1 (ko) | 2006-08-21 |
| CA2450548A1 (en) | 2002-12-27 |
| US7348423B2 (en) | 2008-03-25 |
| CA2450548C (en) | 2012-05-01 |
| ES2525317T3 (es) | 2014-12-22 |
| KR20060035814A (ko) | 2006-04-26 |
| JP2004529660A (ja) | 2004-09-30 |
| EP1402050A2 (en) | 2004-03-31 |
| EP1402050B1 (en) | 2014-10-29 |
| CN1516738A (zh) | 2004-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2443365A1 (en) | Methods for the recombinant production of antifusogenic peptides | |
| EP1392717A4 (en) | FAST CLEAVABLE SUMOFUSION PROTEIN EXPRESSION SYSTEM FOR HEAVY-TO-EXPRESS PROTEINS | |
| WO1995003405A3 (en) | Enzymatic method for modification of recombinant polypeptides | |
| FI934812A0 (fi) | Stabiliserade entzymer | |
| MXPA03011453A (es) | Acetilacion de fragmentos de gp41. | |
| AU1283288A (en) | Production and purification of a protein fused to a binding protein | |
| WO2002052029A9 (fr) | Methode permettant de produire une proteine de recombinaison et une proteine fusionnee | |
| EP0528686B8 (en) | Process for producing peptides | |
| CA2379571A1 (en) | Process for the production of a heterologous peptide by autoproteolytic cleavage in vitro | |
| JPS60500043A (ja) | 原核細胞又は真核細胞中で合成される融合蛋白質から成熟蛋白質を作る方法 | |
| US8530217B2 (en) | Processing of peptides and proteins | |
| KR970065554A (ko) | 프로세싱 효소를 사용한 키메라 단백질의 절단 방법 | |
| HUP0203051A2 (hu) | Fehérjék előállítása autoproteolitikus hasítással | |
| EP0300459A3 (en) | Human pancreatic secretory trypsin inhibitor | |
| DE69634757D1 (de) | Vektor zur expression von n-terminal verlängerten proteinen in hefezellen | |
| AU1717402A (en) | Glucuronyl c5-epimerase, dna encoding the same and uses thereof | |
| IE883462L (en) | A method for the selective cleavage of fusion proteins | |
| SCHELLENBERGER et al. | Peptide production by a combination of gene expression, chemical synthesis, and protease‐catalyzed conversion | |
| EP1697509B1 (en) | Processing of peptides and proteins | |
| EP0750040A3 (en) | Macrophage stimulating protein variant and method for producing the same | |
| S Esipov et al. | Production of recombinant oxytocin through sulfitolysis of inteincontaining fusion protein | |
| Cannio et al. | Identification of a cell-bound extracellular protease overproduced by Sulfolobus solfataricus in peptide-rich media | |
| Likhareva et al. | Synthetic model and bioactive peptides as potential substrates for enteropeptidase | |
| EP0635573A2 (en) | Process for the preparation of native human glicentin | |
| EP0945512A3 (en) | Novel serine proteases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |